Phase 2 Leukaemia Trial, Recruiting NCT06621199 Sponsor: First Affiliated Hospital of Zhejiang University Condition: Leukaemia
Back to Leukaemia

Phase 2 Leukaemia Trial, Recruiting

NCT06621199
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are willing to sign a consent form showing you understand the study and agree to take part
  • You are between 60 and 70 years old (including those who are exactly 60 or 70)
  • You have been newly diagnosed with a type of blood cancer called Acute Myeloid Leukemia (AML), confirmed using the latest medical guidelines (WHO 2022)
  • You are generally able to carry out basic daily activities (ranging from fully active to capable of limited self-care)
  • Your doctors expect you to live for at least 3 months
  • Your liver and kidney function test results are within acceptable ranges (confirm with trial site for exact values)

Who may not be able to join:

  • You have a specific subtype of AML called Acute Promyelocytic Leukemia
  • Your AML developed as a result of previous chemotherapy or radiotherapy for another cancer, or from a prior blood disorder
  • Your AML developed from a previous condition called Chronic Myeloid Leukemia
  • The leukemia has spread to your brain or spinal fluid
  • You have had another cancer in the past 5 years (with some exceptions, such as certain treated skin or cervical cancers — confirm with trial site)
  • You have already received certain chemotherapy treatments for AML (some white blood cell-lowering treatments may be acceptable — confirm with trial site)
  • You have taken certain medications that affect how drugs are processed by the body within the 7 days before starting the trial (confirm with trial site for the specific medications)
  • You are unable to swallow tablets or pills, or your body cannot properly absorb oral medications
  • You have certain heart conditions, including irregular heartbeat, a history of heart attack, heart failure, or reduced heart pumping function (confirm with trial site for full details)
  • You have uncontrolled ongoing illnesses such as serious infections, uncontrolled high blood pressure, or uncontrolled diabetes
  • You have HIV (confirmed by a positive HIV antibody test)
  • You have active Hepatitis B or Hepatitis C infections with detectable virus levels in your blood
  • You have had a serious allergic reaction to drugs similar to the one being studied
  • You have a history of severe neurological or psychiatric illness
  • The trial doctor decides for any other reason that the trial is not appropriate for you

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 20 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: +86 571-87236896

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
First Affiliated Hospital of Zhejiang University
Registry
ClinicalTrials.gov
Start date
8 July 2024
Est. completion
31 December 2027

Where this trial is recruiting

🇨🇳 China

Primary endpoints

2-year event-free survival (EFS) rate

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 20 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov